Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00333502 · ClinicalTrials.gov registry record · Phase 1
Study of CRLX101 (NLG207) in the Treatment of Advanced Solid Tumors
A Phase 1 study, sponsored by NewLink Genetics Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 62
- Enrollment target
NCT00333502 is a Phase 1 study that has completed, run by NewLink Genetics Corporation. The registered enrollment target is 62 participants.
The verdict
NCT00333502, a Phase 1 study, has completed, sponsored by NewLink Genetics Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 62 participants
- Enrollment target
Study Summary
CRLX101 is a nanopharmaceutical comprised of the chemotherapeutic camptothecin (CPT) conjugated to a linear, cyclodextrin-based polymer. CRLX101 is designed to increase the exposure of tumor cells to CPT while minimizing side effects. OBJECTIVES: • Determine the safety, toxicity, and the maximum tolerated dose (MTD) of CRLX101 when administered intravenously to subjects with advanced solid tumors.
Interventions
- DRUG Camptothecin (CPT) conjugated to a linear, cyclodextrin-based polymer
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2006-05 |
| Est. Completion | 2012-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00333502
The ClinicalTrials.gov registry entry for NCT00333502 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NewLink Genetics Corporation, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Camptothecin (CPT) conjugated to a linear, cyclodextrin-based polymer is the first listed.
NCT00333502 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00333502 about?
NCT00333502 is a clinical study titled "Study of CRLX101 (NLG207) in the Treatment of Advanced Solid Tumors". CRLX101 is a nanopharmaceutical comprised of the chemotherapeutic camptothecin (CPT) conjugated to a linear, cyclodextrin-based polymer. CRLX101 is designed to increase the exposure of tumor cells to CPT while minimizing side effects. OBJECTIVES: • Determine the safety, toxicity, and the maximum t...
What is the current status of trial NCT00333502?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 62 participants. The study started on 2006-05. Estimated completion is 2012-04.
What interventions are being tested in trial NCT00333502?
The interventions under investigation include: Camptothecin (CPT) conjugated to a linear, cyclodextrin-based polymer (DRUG).
Who is sponsoring clinical trial NCT00333502?
This trial is sponsored by NewLink Genetics Corporation, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.